Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Aflac (AFL) has not had a specific headline event driving the stock recently. This leaves investors focusing on its recent returns, valuation metrics, and the stability of its supplemental insurance business.
See our latest analysis for Aflac.
At a share price of US$109.51, Aflac’s short term share price returns have been fairly muted, while its 1 year, 3 year and 5 year total shareholder returns of 5.1%, 64.7% and 165.0% point to stronger longer term momentum.
If you are comparing Aflac’s steadier profile with more growth focused names, it could be worth scanning healthcare stocks to spot other insurance and health related ideas that fit your watchlist.
With annual revenue of US$17.7b, net income of US$4.2b and a share price close to analyst targets, the key question is whether Aflac’s strong history is already fully reflected in the valuation, or if the market is underpricing its future growth potential.
The most followed narrative sees Aflac’s fair value at about US$111.31, only slightly above the last close of US$109.51. This frames the stock as marginally cheap on its own fundamentals.
Ongoing diversification and optimization of Aflac’s investment portfolio, including the proactive management of yen
Want to see what underpins that modest discount? This narrative focuses on steady revenue expansion, higher profit margins, and a future earnings multiple that requires real conviction to sustain. Curious which exact assumptions make the numbers align, and how the 6.96% discount rate shapes that outcome?
Result: Fair Value of $111.31 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, those assumptions could be challenged if Japan premiums keep shrinking and technology spending in Japan stays high without the expected lift in productivity and margins.
Find out about the key risks to this Aflac narrative.
Our SWS DCF model suggests a very different picture, with Aflac’s fair value at about US$168.61 versus the current US$109.51. This implies the shares are undervalued to a much greater degree than the 1.6% gap in the narrative. Which set of assumptions do you trust more?
Look into how the SWS DCF model arrives at its fair value.
AFL Discounted Cash Flow as at Jan 2026
If you look at the numbers and reach a different conclusion, or simply want to test your own assumptions, you can build a custom Aflac narrative in just a few minutes using Do it your way.
A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Aflac.
If Aflac is already on your radar, do not stop there. Use the Simply Wall Street Screener to quickly surface other opportunities that match your style and risk comfort.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AFL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com